Showing 21-30 of 3039 results for "".
- November/December 2023 Supplement - MOD Issueshttps://modernod.com/mod-issues/novemberdecember-2023-supplement/
26. Dr. Danielle Gordon on Opening Sphere Optometry
https://modernod.com/podcasts/four-eyes/26-dr-danielle-gordon-on-opening-sphere-optometry/36976/We're back with another season of brand new episodes! Today we are sharing our interview with Dr. Danielle Gordon, a Canadian optometrist who opened her private practice, Sphere Optometry, in Calgary, Alberta. Dr. Gordon shares her experience opening a practice as a seasoned optometrist and offers tInitial Visits and Long-term Care of Glaucoma Patients in Primary Eye Care Settings
https://modernod.com/topics/glaucoma/initial-visits-and-long-term-care-of-glaucoma-patients-in-primary-eye-care-settings-1/36866/Which technologies are essential to conducting a thorough examination for new glaucoma patients? And which modalities and softwares are most useful for long-term care? Danica Marrelli, OD, and Anu Laul, OD, compare their approaches to initial encounters with glaucoma patients, swap notes on their prHarrow Adds Biosimilars to US Portfolio
https://modernod.com/podcasts/eyewire-news-the-podcast/harrow-adds-biosimilars-to-us-portfolio/37094/Harrow enters a deal to expand it biosimilar pharma portfolio; the first gene-agnostic therapy to restore vision in RP patients advances; and Aldeyra provides an update on its dry eye drug candidate reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoicesPhase 3 Results for Novel Sedation Tablet
https://modernod.com/podcasts/eyewire-news-the-podcast/phase-3-results-for-novel-sedation-tablet/37062/New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment. Learn more about your ad choices. Visit megaphone.fm/adchoicesTryptyr Now Available in US
https://modernod.com/podcasts/eyewire-news-the-podcast/tryptyr-now-available-in-us/37095/Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment. Learn more about your ad choices. Visit megaphone.fm/adchoicesNorlase Launches First Pattern Scanning LIO
https://modernod.com/podcasts/eyewire-news-the-podcast/norlase-launches-first-pattern-scanning-lio/37069/The world’s first and only pattern scanning laser indirect ophthalmoscope is approved in the US and Europe; the European Commission approves a biosimilar to Eylea; and we review several clinical updates in the development of ophthalmic drugs. Learn more about your ad choices. Visit megaphone.fm/adchOphthalmic Leaders Launch SightLine Meeting
https://modernod.com/podcasts/eyewire-news-the-podcast/ophthalmic-leaders-launch-sightline-meeting/37083/Commercial stakeholders discuss the challenges and opportunities in ophthalmology in this special edition of Eyewire News: The Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoicesVisionary Breakthroughs: A Spotlight on Innovations in Eye Care (Part 2 of 2)
https://modernod.com/podcasts/eyewire-news-the-podcast/visionary-breakthroughs-a-spotlight-on-innovations-in-eye-care-part-2-of-2/39873/Industry executives discuss future innovations and breakthroughs that are poised to reshape the future of ophthalmic care. Learn more about your ad choices. Visit megaphone.fm/adchoicesVisionary Breakthroughs: A Spotlight on Innovations in Eye Care (Part 1 of 2)
https://modernod.com/podcasts/eyewire-news-the-podcast/visionary-breakthroughs-a-spotlight-on-innovations-in-eye-care-part-1-of-2/39872/Industry executives discuss future innovations and breakthroughs that are poised to reshape the future of ophthalmic care. Learn more about your ad choices. Visit megaphone.fm/adchoices